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INTRODUCTION
Lung cancer is the leading cause of cancer mor-
tality in developed countries, and its incidence con-
tinues to increase (1). In spite of the improvement
in both diagnosis and treatment, the prognosis of
patients with advanced lung cancer is still poor (2).
Thus, when treating advanced lung cancer patients,
it is essential to make an effort to maintain patient’s
quality of life (QOL) without decreasing the qual-
ity of treatment. In this point of view, outpatient
chemotherapy has been considered to contribute
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to maintain QOL of cancer patients (3), and in many
facilities outpatient chemotherapy has become stan-
dard treatment strategy.
The first-line platinum based combination chemo-
therapy and the second-line chemotherapy with do-
cetaxel are currently recommended as the standard
approach for chemotherapy-naïve patients with ad-
vanced lung cancer and NSCLC patients who are re-
fractory to the first-line chemotherapy, respectively
(4, 5). On the basis of randomized phase III studies,
it is clearly shown that these therapeutic strategies
prolong the survival and that improve patient’s
QOL by controlling disease-related symptoms (6).
However, these evidences were usually obtained
from non-elderly patients with good performance
status. In the clinical setting, we often encounter
advanced lung cancer patients in the elderly and/
or with declined performance status, who are not
eligible for usual eligibility criteria of randomized
phase III studies. For these patients, we can hardly
indicate the standard chemotherapeutic regimens
and no established alternative regimens are dem-
onstrated. Therefore, it seems important to under-
stand the current status of chemotherapy for lung
cancer in the settings of clinical practice. In this re-
port, we focused on outpatient chemotherapy which
has been done in our department and retrospec-
tively analyzed the efficacy of the treatments, fre-
quency of adverse events as well as QOL of the pa-
tients.
PATIENTS AND METHODS
Patients
The retrospective analysis was conducted using
data from patients who had diagnosed as lung can-
cer in the Department of Respiratory Medicine and
Rheumatology in Tokushima University Hospital.
Examination of patient records from January 2007
to August 2008, revealed that 94 cases were found
to fit the eligibility criteria (Different chemotherapy
regimens in one patient were analyzed as separate
cases).
Eligibility Criteria
Patients were required to have histological or cy-
tological confirmation of lung cancer ; life expec-
tancy 12 weeks ; adequate bone marrow, hepatic
and renal function ; with the presence of at least
one measurable indicator lesion assessed by con-
ventional computed tomography scan. The patients
who received at least one chemotherapeutic regi-
men in outpatient chemotherapy unit in Tokushima
University Hospital were enrolled in this study. The
patients had to give written informed consent for
receiving outpatient chemotherapy.
Chemotherapy
For the treatment, clinically approved anti-cancer
drugs were used. Generally, patients were admitted
to the hospital to receive first cycle of the treatment.
After confirming the level of adverse events, follow-
ing treatment was performed at the outpatient clinic.
All adverse events were graded according to Com-
mon Terminology Criteria for Adverse Events ver-
sion 3.0 (CTCAE v3.0) (7). When grade 4 hema-
tologic toxicities and/or grade 3 or worse non-
hematologic toxicities were occurred, the dosage of
the drug was reduced to 80% of original dose. The
use of molecular-targeted agents such as epidermal
growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) was not investigated in this study.
Objective Tumor Response, Time to Treatment Fail-
ure, Quality of Life
Response was determined in comparison with
baseline assessment of measurable disease or evalu-
able disease and confirmed 4 weeks later. Objec-
tive tumor responses were defined as complete re-
sponse (CR), partial response (PR), stable disease
(SD) or progressive disease (PD), using Response
Evaluation Criteria in Solid Tumors (RECIST) ver-
sion 1.0 (8). Best overall response (BOR) was de-
fined as the best objective response during chemo-
therapy. TTF was calculated from the date of the
initiation of treatment up to the date of failure (de-
fined as progression, relapse, death, withdrawal due
to adverse events, patient’s refusal, loss to follow-
up or start of new anticancer therapy) (9).
Statistical Analysis
Survival curves were estimated by the Kaplan-
Meier method. The log-rank test was used to com-
pare patient’s survival between groups. p0.05 was
considered to be statistically significant.
RESULTS
Data have been obtained retrospectively for 94
out of more than 100 cases with lung cancer. The
characteristics of the patients are shown in Table 1.
Among 94 cases, there were 81 (86.2%) men and 13
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(13.8%) women with mean age of 67 years (range :
36-86 years old). Sixty-nine (73.4%) cases had stage
IV lung cancer and 81 (86.2%) had Eastern Coopera-
tive Oncology Group (ECOG) performance status
of 0 or 1. In terms of histological background, 67
(71.3%) cases were NSCLC and 27 (28.7%) were
SCLC. Among NSCLC, adenocarcinoma was the
most commonly seen, followed by squamous cell
carcinoma, large cell carcinoma. Compared to the
previous report (10), the frequency of adenocarci-
noma was lower and that of small cell lung cancer
was higher in this study.
The different chemotherapy regimens received
by these patients for each line treatment are shown
in Table 2. Patients had received platinum-based
therapy as first-line (94.3%) or second-line (43.3%)
treatment. Twenty-four out of 27 cases (88.9%) with
SCLC were treated with platinum-based therapy ir-
respective of treatment line. In NSCLC, 21 out of
23 patients (91.3%) received platinum-based therapy
Table 1. Patient characteristics
No. cases 94
Male/Female 81/13
Age (Years)
Median (Range) 67 (36-86)
ECOG Performance Status
0 12 (12.8%)
1 69 (73.4%)
2 13 (13.8%)
Stage
IIB 4 ( 4.3%)
IIIA 4 ( 4.3%)
IIIB 17 (18.1%)
IV 69 (73.4%)
Histology
NSCLC
Adenocarcinoma 38 (40.4%)
Squamous cell carcinoma 20 (21.3%)
Large cell carcinoma 5 ( 5.3%)
Unknown 4 ( 4.3%)
SCLC 27 (28.7%)
Table 2A. Chemotherapy regimens for small cell lung cancer
Regimen
treatment line
total
1st (n=12) 2nd (n=10) 3rd (n=2) 4th or more (n=3)
Platinum-based (%) 12 (100.0) 9 (90.0) 1 (50.0) 2 (66.7)
CBDCA+CPT-11 8 6 1 2 17
CBDCA+VP-16 2 2 4
CDDP+CPT-11 2 1 3
Others (%) 0 (0.0) 1 (10.0) 1 (50.0) 1 (33.3)
AMR 1 1 1 3
total 12 10 2 3 27
Table 2B. Chemotherapy regimens for non-small cell lung cancer
Regimen
treatment line
total
1st (n=23) 2nd (n=20) 3rd (n=12) 4th or more (n=12)
Platinum-based (%) 21 (91.3) 4 (20.0) 0 (0.0) 0 (0.0)
CBDCA+VNR 8 1 9
CBDCA+PTX 5 1 6
CDDP+VNR 3 1 4
CBDCA+GEM 2 1 3
CBDCA+DTX 2 2
CDDP+GEM 1 1
Others (%) 2 (8.7) 16 (80.0) 12 (100.0) 12 (100.0)
VNR 1 2 3
CPT-11 1 3 4
DTX 8 9 3 20
GEM+VNR 5 1 6
GEM 1 2 5 8
AMR 1 1
total 23 20 12 12 67
CBDCA : Carboplatin, CPT-11 : Irinotecan, VNR : Vinorelbine, PTX : Paclitaxel, CDDP : Cisplatin, VP-16 : Etoposide, GEM : Gemcitabine,
DTX : Docetaxel, AMR : Amrubicin
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as first-line chemotherapy, while as second-line che-
motherapy, 16 patients (80.0%) were treated with
single or combination of non-platinum agents. The
regimens for third or more lines of treatment var-
ied widely.
Among 94 cases, 92 were eligible for the evalu-
ation of objective tumor response assessed by
RECIST version 1.0. As shown in Table 3, 2 CR and
24 PR were observed in the 92 assessable cases
for overall response rate was 28.3%. The response
rates in SCLC and NSCLC patients were 55.6% (15/
27) and 16.9% (11/65), respectively. The overall dis-
ease control rate (response plus SD) was 94.6% (87/
92), indicating the diseases of almost all patients
were controlled by the chemotherapy at least 2
months. We next evaluated the response rates for
each line of treatment. Objective tumor response
rates for the patients were found to decrease sub-
stantially with each line of treatment (Fig. 1). The
response rates of the first, second, third and fourth
or more lines of treatment for SCLC and NSCLC
were 83.3% and 38.1%, 50.0% and 15.0%, 0% and 0%,
0% and 0%, respectively.
Grade 3-4 adverse events of chemotherapy, as-
sessed by CTCAE v3.0, are shown in Table 4. The
frequencies of grade 3-4 toxicities observed in the
present study were comparable with the previous
reports (11, 12). The most common grade 3-4 tox-
icities were leukopenia and neutropenia, which were
seen in 18 (19.1%) and 22 (23.4%) of lung cancer
patients, respectively. All adverse events were well
Figure 1 Response rates for each line of chemotherapy in
SCLC and NSCLC patients.
Table 4. Common Terminology Criteria for Adverse Events
version 3.0 grade 3-4 toxicity.
Adverse events
Number of patients (%)
G3 G4 G3+G4
Hematological toxicities
Leukopenia 17 (18.1) 1 ( 1.1) 18 (19.1)
Neutropenia 11 (11.7) 11 (11.7) 22 (23.4)
Anemia 6 ( 6.4) 1 ( 1.1) 7 ( 7.4)
Thrombocytepenia 3 ( 3.2) 0 ( 0.0) 3 ( 3.2)
Hyponatremia 1 ( 1.1) 0 ( 0.0) 1 ( 1.1)
Non-hematological toxicities
Infection 6 ( 6.4) 0 ( 0.0) 6 ( 6.4)
Pulmonary disorder 3 ( 3.2) 0 ( 0.0) 3 ( 3.2)
Anorexia 1 ( 1.1) 0 ( 0.0) 1 ( 1.1)
Diarrhea 1 ( 1.1) 0 ( 0.0) 1 ( 1.1)
Table 3A. Best overall response (BOR) in each line of chemotherapy for small cell lung cancer.
BOR
treatment line
total (%)
1st (n=12) 2nd (n=10) 3rd (n=2) 4th or more (n=3)
Complete response 1 1 (3.7)
Partial response 9 5 14 (51.9)
Stable disease 2 5 2 9 (33.3)
Progressive disease 3 3 (11.1)
Not evaluable 0 (0.0)
total 12 10 2 3 27
Table 3B. Best overall response (BOR) in each line of chemotherapy for non-small cell lung cancer.
BOR
treatment line
total (%)
1st (n=23) 2nd (n=20) 3rd (n=12) 4th or more (n=12)
Complete response 1 1 (1.5)
Partial response 7 3 10 (14.9)
Stable disease 13 17 11 11 52 (77.6)
Progressive disease 1 1 2 (3.0)
Not evaluable 2 2 (3.0)
total 23 20 12 12 67
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tolerated and no grade 5 toxicities were seen in the
present study. The reasons of emergency admission
throughout chemotherapy are shown in Table 5.
Fifteen out of 94 cases were forced unscheduled
admission to our hospital. Infectious diseases, such
as pneumonia, in accordance with neutropenia were
prominent. The rate of emergency admission during
chemotherapy was 16.0%, which was comparable
with the report that 20.8% of cases required hospital
admission during outpatient chemotherapy (13).
Finally, we examined the TTFs of first-line and
second or more lines of chemotherapy (Fig. 2). In
SCLC, median TTFs of first-line and second or more
lines of treatment were 304 days (10.1 months) and
145 days (4.8 months), respectively. In NSCLC, me-
dian TTFs of first-line and second or more lines of
treatment were 188 days (6.3 months) and 132 days
(4.4 months), respectively. Median TTFs of first-
line chemotherapy tended to be longer than that of
second or more lines in both SCLC and NSCLC, but
not significant (p=0.1620 and 0.3650, respectively).
The median TTFs observed in the present study
were comparable with previously reported results
(14), strongly indicating that the efficacy of chemo-
therapy might be retained by the appropriate thera-
peutic management even in the setting of clinical
practice, such as outpatient chemotherapy unit.
DISCUSSION
In the present study, we investigated the current
status of outpatient chemotherapy for lung cancer.
Even in the setting of clinical practice, the efficacy,
which was assessed by the response rate and the
TTF, and the safety of chemotherapeutic agents
were demonstrated to be comparable with the pre-
viously reported results in randomized phase III
studies.
Platinum-doublet regimens combining cisplatin
or carboplatin with etoposide, irinotecan are exten-
sively administered for the first-line chemotherapy
in SCLC. In a multicenter, randomized, phase III
study to compare irinotecan plus cisplatin with
etoposide plus cisplatin in patients with extensive
SCLC, the response rates and the progression-free
survivals were reported to be 67.5-84.4% and 4.8-6.9
months, respectively (11). For advanced NSCLC pa-
tients, combination chemotherapy, usually platinum-
based, is also currently the first-line therapy of
choice (15). Based on various studies, doublet regi-
mens combining cisplatin or carboplatin with pacli-
taxel, gemcitabine, docetaxel, vinorelbine or irinote-
can are chosen. Various studies have shown similar
degrees of efficacy among different combinations in
Table 5. The reason of emergency admission during chemo-
therapy.
Events No. of patients (%)
Pneumonia 5 ( 5.3)
Pulmonary disorder 3 ( 3.2)
Infection 2 ( 2.1)
Anorexia 1 ( 1.1)
Hemosputum 1 ( 1.1)
Numbness in extremities 1 ( 1.1)
Pain 1 ( 1.1)
Terminal care 1 ( 1.1)
Total 15 (16.0)
Figure 2 Kaplan-Meier curve showing time to treatment failure of SCLC and NSCLC patients who received 1st or 2nd or more
chemotherapy.
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the treatment of advanced NSCLC. For instance,
in a randomized phase III trial including over 100
patients in each study group, cisplatin plus irinote-
can was compared with cisplatin or carboplatin plus
paclitaxel, gemcitabine or vinorelbine. No significant
differences were reported in terms of the efficacy
of these four chemotherapeutic regimens ; in each
arm, the response rates were 30.1-33.1%, and the
median TTFs were 3.0-3.3 months (14). In the pre-
sent study, the clinical efficacy of the first-line che-
motherapy for SCLC and NSCLC patients were com-
parable with previously reported results ; in each
group, the response rates were 83.3% and 38.1%
(Table 3), the median TTFs were 10.1 months and
6.3 months (Fig. 2), respectively. These results in-
dicate that the efficacy of chemotherapy might be
retained by the appropriate therapeutic management
even in the setting of clinical practice, such as out-
patient chemotherapy unit.
The objective tumor response rates and the me-
dian overall survival time for lung cancer are well
known to decrease substantially with each line of
chemotherapy. The response rates and the median
overall survival time of the first, second, third and
fourth lines of treatment for advanced NSCLC were
reported to be 20.9% and 15.7 months, 16.3% and 9.8
months, 2.3% and 5.4 months, 0% and 5.9 months,
respectively (16). In the present study, the response
rates of the first, second, third or more lines of treat-
ment for NSCLC were 38.1%, 15.0%, and 0%, respec-
tively (Table 3, Fig. 1), in consistent with previous
reports.
When treating patients with cancer, physicians
usually seek the best therapeutic results. However,
patients do not always have exactly the same pri-
orities when setting therapeutic goals. Generally,
patients wish to experience symptom improvement,
few toxic effects and better quality of life, in addi-
tion to expect to live longer. A study conducted by
Silvestri et al , which enrolled 81 patients with ad-
vanced NSCLC already treated with chemotherapy,
showed that many patients would choose chemo-
therapy treatment for its effects on quality of life
rather than for the potential survival offered by the
treatment (17). Only 25% would choose chemother-
apy if benefits were exclusively related to survival.
More recently, it was noted that nearly 75% of pa-
tients would choose the therapeutic regimen ac-
cording to the related adverse effects (18). Thus,
because advanced lung cancer is unlikely to be
cured, we always must take the risk of adverse ef-
fects into account when introducing chemotherapy,
especially in outpatient clinic-based treatment.
In the present study, 19.1%, 23.4%, 7.4% and 3.2%
of lung cancer patients developed grade 3 or worse
leukopenia, neutropenia, anemia and thrombocy-
topenia, respectively. Grade 3 or worse infections
including bacterial pneumonia, pulmonary disorders,
diarrhea and anorexia occurred in 6.4%, 3.2%, 1.1%
and 1.1%, respectively, of lung cancer patients. The
incidence of hematologic and non-hematologic tox-
icities was comparable with the previously reported
results in randomized phase III studies (14). All
adverse events were well tolerated and no grade 5
toxicities were developed in the present study.
Moreover, the rate of emergency admission during
chemotherapy was 16.0%, which was comparable
with the report that 20.8% of cases required hospi-
tal admission during outpatient chemotherapy (13).
Taken these results into consideration, the safety of
treatment is insured and QOL of the patients with
lung cancer seems to be well maintained during
treatment in outpatient chemotherapy unit in our
hospital.
Several lines of evidence indicate the effectiveness
of multidisciplinary team for the management of
lung cancer. Coory et al have demonstrated that the
intervention of multidisciplinary team leads to an
increase in the percentage of patients undergoing
surgical resection or an increase in the percentage
of patients undergoing chemotherapy or radiother-
apy with curative intent (19). Moreover, it seems in-
tuitively obvious that multidisciplinary teams should
improve outcomes for lung cancer patients, while
currently available evidence is limited. In our insti-
tution, we are scheduled to launch multidisciplinary
team, including certified nurses and pharmacists, to
discuss the diagnosis and management of patients
with lung cancer.
In conclusion, we investigated the current status
of chemotherapy for lung cancer in outpatient che-
motherapy unit in Tokushima University Hospital.
Even in the setting of clinical practice, the efficacy
and safety of chemotherapy was demonstrated is
strictly insured by the appropriate therapeutic man-
agement.
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